These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

749 related items for PubMed ID: 25501326

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
    Koolen BB, Valdés Olmos RA, Elkhuizen PH, Vogel WV, Vrancken Peeters MJ, Rodenhuis S, Rutgers EJ.
    Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522
    [Abstract] [Full Text] [Related]

  • 43. [18F]Fluorodeoxyglucose-positron emission tomography/computed tomography response evaluation can predict histological response at surgery after induction chemotherapy for oligometastatic bladder cancer.
    Kollberg P, Almquist H, Bläckberg M, Cwikiel M, Gudjonsson S, Lyttkens K, Patschan O, Liedberg F.
    Scand J Urol; 2017 Aug; 51(4):308-313. PubMed ID: 28532260
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Predictive Value of 18F-FDG PET/CT for Axillary Lymph Node Metastasis in Invasive Ductal Breast Cancer.
    Song BI, Kim HW, Won KS.
    Ann Surg Oncol; 2017 Aug; 24(8):2174-2181. PubMed ID: 28432480
    [Abstract] [Full Text] [Related]

  • 47. 18F-FDG PET/CT can predict chemosensitivity and proliferation of epithelial ovarian cancer via SUVmax value.
    Liu S, Feng Z, Wen H, Jiang Z, Pan H, Deng Y, Zhang L, Ju X, Chen X, Wu X.
    Jpn J Radiol; 2018 Sep; 36(9):544-550. PubMed ID: 29943313
    [Abstract] [Full Text] [Related]

  • 48. Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients.
    Hahn S, Hecktor J, Grabellus F, Hartung V, Pöppel T, Kimmig R, Forsting M, Antoch G, Heusner TA.
    Acta Radiol; 2012 Jun 01; 53(5):518-23. PubMed ID: 22547387
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Role of 18F-PET/CT in Predicting Prognosis of Patients With Breast Cancer After Neoadjuvant Chemotherapy.
    Akimoto E, Kadoya T, Kajitani K, Emi A, Shigematsu H, Ohara M, Masumoto N, Okada M.
    Clin Breast Cancer; 2018 Feb 01; 18(1):45-52. PubMed ID: 28993056
    [Abstract] [Full Text] [Related]

  • 52. Predictive and prognostic value of FDG-PET/CT imaging and different response evaluation criteria after primary systemic therapy of breast cancer.
    Tőkés T, Kajáry K, Szentmártoni G, Lengyel Z, Györke T, Torgyík L, Somlai K, Tőkés AM, Kulka J, Dank M.
    Breast Cancer; 2017 Jan 01; 24(1):137-146. PubMed ID: 26979062
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Value of 18F-FDG PET/CT for early prediction of pathologic response (by residual cancer burden criteria) of locally advanced breast cancer to neoadjuvant chemotherapy.
    Lee SM, Bae SK, Kim TH, Yoon HK, Jung SJ, Park JS, Kim CK.
    Clin Nucl Med; 2014 Oct 01; 39(10):882-6. PubMed ID: 25072926
    [Abstract] [Full Text] [Related]

  • 55. Prone Versus Supine Breast FDG-PET/CT for Assessing Locoregional Disease Distribution in Locally Advanced Breast Cancer.
    Abramson RG, Lambert KF, Jones-Jackson LB, Arlinghaus LR, Williams J, Abramson VG, Chakravarthy AB, Yankeelov TE.
    Acad Radiol; 2015 Jul 01; 22(7):853-9. PubMed ID: 25865435
    [Abstract] [Full Text] [Related]

  • 56. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Kauppi JT, Oksala N, Salo JA, Helin H, Karhumäki L, Kemppainen J, Sihvo EI, Räsänen JV.
    Acta Oncol; 2012 May 01; 51(5):636-44. PubMed ID: 22208782
    [Abstract] [Full Text] [Related]

  • 57. 18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Vallius T, Peter A, Auranen A, Carpén O, Kemppainen J, Matomäki J, Oksa S, Roering P, Seppänen M, Grénman S, Hynninen J.
    Gynecol Oncol; 2016 Jan 01; 140(1):29-35. PubMed ID: 26515076
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. 18F-FDG PET-CT imaging in the neoadjuvant setting for stages II-III breast cancer: association of loco‑regional SUVmax with classical prognostic factors.
    García García-Esquinas M, García-Sáenz JA, Arrazola García J, Enrique Fuentes Ferrer M, Furió V, Rodriguez Rey C, Román JM, Carreras Delgado JL.
    Q J Nucl Med Mol Imaging; 2014 Mar 01; 58(1):66-73. PubMed ID: 24104854
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 38.